
|Videos|November 5, 2021
Dr. Koontz on study of dose-escalated RT plus androgen suppression in prostate cancer
Author(s)Urology Times staff
Advertisement
In this video, Bridget F. Koontz, MD, provides an expert opinion on the methods and findings of the study, “Dose-escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/RTOG 0815 randomized trial,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5











